You just read:

OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer

News provided by

OncoGenex Pharmaceuticals, Inc.

Aug 16, 2016, 07:00 ET